Novavax | NVAX - Sales Revenues

Stock Price
8.84
Daily Change
0.20 2.31%
Monthly
-11.69%
Yearly
47.09%
Q2 Forecast
8.65

Novavax reported $147.14M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Adma Biologics USD 139.16M 4.94M Dec/2025
Agenus USD 34.2M 3.97M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Geron USD 48.02M 820K Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
MannKind USD 111.96M 29.83M Dec/2025
Merck USD 16.4B 880M Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 678M 342M Dec/2025
Novartis USD 13.86B 498M Dec/2025
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025